Mittendorf T, Dietz B, Sterz R, Cifaldi M A, Kupper H, von der Schulenburg J-M
Center for Health Economics, Gottfried Wilhelm Leibniz University Hannover, Hannover, Germany.
Rheumatology (Oxford). 2008 Feb;47(2):188-93. doi: 10.1093/rheumatology/kem317. Epub 2008 Jan 3.
This study evaluated the patients' perspective of burden of disease among 505 patients with severe, long-standing rheumatoid arthritis receiving adalimumab.
Health-related quality-of-life and resource use data were collected during a 144-week open-label study.
Adalimumab maintained pain control and reduced the duration of morning stiffness. Work impairment decreased and work productivity was maintained over the duration of the study. Costs were estimated at approximately 2100 euros over the course of the study, and personal help and transportation costs comprised a large percentage of total costs.
These results suggest that adalimumab could improve many aspects of a patient's burden of disease.
本研究评估了505例接受阿达木单抗治疗的重度、长期类风湿关节炎患者对疾病负担的看法。
在一项为期144周的开放标签研究中收集了与健康相关的生活质量和资源使用数据。
阿达木单抗维持了疼痛控制并缩短了晨僵持续时间。在研究期间，工作障碍减少，工作效率得以维持。研究过程中的成本估计约为2100欧元，个人帮助和交通成本在总成本中占很大比例。
这些结果表明，阿达木单抗可以改善患者疾病负担的许多方面。
